Macular hemorrhage in neovascular age-related macular degeneration after stabilization with antiangiogenic therapy

Retina

Volumn 29, Issue 8, 2009, Pages 1074-1079

  Levine, Jonathan P ^a   Marcus, Inna ^b   Sorenson, John A ^c,d   Spaide, Richard F ^c,d   Cooney, Michael J ^c,d   Freund, K Bailey ^c,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^d EAR AND THROAT HOSPITAL   (United States)

Author keywords

Age related macular degeneration; Bevacizumab; Choroidal neovascularization; Ranibizumab; Subretinal hemorrhage

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID; BEVACIZUMAB; BRIMONIDINE; CLOPIDOGREL; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; RANIBIZUMAB; WARFARIN;

AGED; ANTIANGIOGENIC THERAPY; CAROTID ARTERY OBSTRUCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA; GONIOSCOPY; HUMAN; INTRAOCULAR PRESSURE; IRIDOTOMY; MALE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HEMORRHAGE; REVIEW; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MACULA LUTEA; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETINAL HEMORRHAGE; RETINAL NEOVASCULARIZATION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349145467     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181b09443     Document Type: Review

References (12)

1. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
2. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
3. Stone EM. A very effective treatment for neovascular macular degeneration. N Engl J Med 2006;355:1493-1495.
4. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-372.
5. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007; 143:679-680.
6. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovas-cular age-related macular degeneration. Ophthalmology 2006; 113:363-372.e5.
7. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143:566-583.
8. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006;355:1409-1412.
9. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neo-vascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
10. Barbazetto et al. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab. Presented at the Annual Meeting of the Retina Society; September 2008.
11. Scupola A, Coscas G, Soubrane G, Balestrazzi E. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica 1999;213:97-102.
12. Tilanus MA, Vaandrager W, Cuypers MH, Verbeek AM, Hoyng CB. Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2000;238: 482-485.